Elevated levels of plasma low density lipoprotein (LDL)-cholesterol, leading to familial
hypercholesterolemia, are enhanced by mutations in at least three major genes, the LDL …

PCSK9 is a secreted protein that degrades low density lipoprotein receptors (LDLRs) in liver
by binding to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR. It is not …

PCSK9 enhances the cellular degradation of the LDL receptor (LDLR), leading to increased
plasma LDL cholesterol. This multidomain protein contains a prosegment, a catalytic …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that controls
plasma LDL cholesterol levels by posttranslational regulation of the LDL receptor (LDLR) …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K
subfamily of subtilases, promotes internalization and degradation of low density lipoprotein …

PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR
[LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to …

Mutations within PCSK9 (proprotein convertase subtilisin/kexin type 9) are associated with
dominant forms of familial hyper-and hypocholesterolemia. Although PCSK9 controls low …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that promotes
degradation of cell surface LDL receptors (LDLRs) in selected cell types. Here we used …

The proprotein convertase PCSK9 gene is the third locus implicated in familial
hypercholesterolemia, emphasizing its role in cardiovascular diseases. Loss of function …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) posttranslationally regulates hepatic
low-density lipoprotein receptors (LDLRs) by binding to LDLRs on the cell surface, leading …